Atorvastatin Clinical Trials

All Categories Medications / Interventions » Aa » Atorvastatin

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Condition: HIV Dementia
Interventions: Drug: Lipitor; Drug: placebo
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified May 2012
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

Condition: Coronary Artery Disease
Interventions: Drug: standard of care lipid therapy (Zocor, Lipitor, Crestor); Drug: Aggressive lipid therapy with Crestor 40mg
Sponsors: Mount Sinai School of Medicine; Annapoorna Kini
Recruiting - verified March 2012
Genetic Influence on Statin Pharmacokinetics

Conditions: Hyperlipidemia; Hypercholesterolemia; Dyslipidemia
Intervention:
Sponsors: Ohio State University; Ohio State University; National Institute of General Medical Sciences (NIGMS)
Recruiting - verified March 2012
Genetic Influence on Statin Pharmacodynamics

Conditions: Hyperlipidemia; Hypercholesterolemia; Dyslipidemia
Intervention:
Sponsors: Ohio State University; Ohio State University; National Institute of General Medical Sciences (NIGMS)
Recruiting - verified March 2012
Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: atorvastatin calcium; Drug: placebo
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified March 2012
Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

Condition: Saphenous Vein Graft Disease
Interventions: Drug: Atorvastatin 80 mg daily; Drug: Atorvastatin 10 mg daily
Sponsors: Boca Raton Regional Hospital; Boca Raton Regional Hospital; Pfizer
Recruiting - verified March 2012
Donor Atorvastatin Calcium in Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Atorvastatin Calcium-Treated Donor Peripheral Blood Stem Cell Transplant in Preventing Severe Graft-Versus-Host Disease in Patients With Hematological Malignancies

Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Previously Treated Myelodysplastic Syndromes; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: atorvastatin calcium; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: atorvastatin; Drug: Tacrolimus; Drug: methotrexate
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified January 2012
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.

Condition: Cardiovascular Diseases
Interventions: Drug: AMR101; Drug: Placebo
Sponsors: Amarin Pharma Inc.; Amarin Pharma Inc.
Recruiting - verified March 2012
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012
Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

Condition: Stroke
Interventions: Drug: Anti-platelets and statin; Drug: alteplase; Procedure: intra arterial intervention
Sponsors: Jacobs Neurological Institute; Jacobs Neurological Institute; University at Buffalo Neurosurgery; Genentech
Recruiting - verified March 2012
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

Condition: Kawasaki Disease
Intervention: Drug: Atorvastatin
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified September 2011
Diabetic Treatment Adherence

Condition: Endocrine System Diseases
Interventions: Drug: Metformin; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012
Modulation of Monocyte Activation by Atorvastatin in HIV Infection

Condition: HIV Dementia
Intervention: Drug: Atorvastatin
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011
Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Conditions: Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Atorvastatin Placebo
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Pfizer; Medtronic; Quest Diagnostics
Recruiting - verified May 2012
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)

Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe (+) atorvastatin; Drug: Comparator: ezetimibe (+) atorvastatin; Drug: Comparator: atorvastatin, switching to ezetimibe (+) atorvastatin; Drug: Comparator: atorvastatin; Drug: Comparator: rosuvastatin, switching to ezetimibe (+) atorvastatin; Drug: Comparator: rosuvastatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
To Investigate the Role of Upstream High Dose Statin in STEMI

Condition: Acute Myocardial Infarction
Interventions: Drug: Atorvastatin calcium; Drug: Inactive Placebo
Sponsors: The Western Pennsylvania Hospital; The Western Pennsylvania Hospital; West Penn Allegheny Health System
Recruiting - verified August 2011
Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Procedure: Percutaneous coronary intervention; Procedure: Intravascular ultrasound with virtual histology; Drug: Atorvastatin; Device: LDL-apheresis
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Condition: Coronary Artery Disease
Intervention: Drug: Atorvastatin
Sponsors: Indiana University; Indiana University School of Medicine; National Center for Research Resources (NCRR)
Recruiting - verified November 2010
Statin Therapy to Improve Atherosclerosis in HIV Patients

Conditions: Cardiovascular Disease; HIV; Atherosclerosis; Inflammation; Statins, HMG-CoA; HIV Infections
Interventions: Drug: atorvastatin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Atorvastatin Three Year Pediatric Study

Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial

Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

Conditions: Acute Kidney Injury; Post-Operative Delirium; Icu Delirium; Acute Renal Failure; Delirium
Interventions: Drug: atorvastatin; Drug: placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified July 2011
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

Condition: HDL Cholesterol
Interventions: Drug: Simvastatin; Drug: Atorvastatin 80 mg
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Merck; Oregon State University; Indiana University
Recruiting - verified August 2008
Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012
Atorvastatin to Treat Pulmonary Sarcoidosis

Condition: Sarcoidosis, Pulmonary
Intervention: Drug: Atorvastatin
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011
Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

Conditions: Leukemia; Lymphoma, Non-Hodgkin
Interventions: Drug: Atorvastatin; Procedure: CT scan of chest/abdomen/pelvis
Sponsors: Stanford University; Stanford University; The Leukemia and Lymphoma Society; Damon Runyon Cancer Research Foundation; Burroughs Wellcome
Recruiting - verified November 2011